

GLAXOSMITHKLINE PLC

Form 6-K

November 08, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending November 2012

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date:8 November 2012

Name of applicant:	GlaxoSmithKline plc
Name of scheme:	GlaxoSmithKline Share Option Plan - Ordinary Shares
Period of return:	From: 1 May 2012 To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:	14,090,687
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	4,373,486
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	9,717,201

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date:8 November 2012

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	GlaxoSmithKline Share Option Plan - ADS		
Period of return:	From:	1 May 2012	To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:		5,537,568	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		10,000,000	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		7,175,490	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		8,362,078	

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8 November 2012

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	Glaxo Wellcome UK Share Option Scheme		
Period of return:	From:	1 May 2012	To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:		5,119,750	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		5,119,750	

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date:8 November 2012

Name of applicant:	GlaxoSmithKline plc
Name of scheme:	Glaxo Wellcome International Share Option Scheme
Period of return:	From: 1 May 2012 To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:	13,267,156
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	13,267,156

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date:8 November 2012

Name of applicant:	GlaxoSmithKline plc
Name of scheme:	Glaxo Wellcome 1999 Share Option Plan
Period of return:	From: 1 May 2012 To: 31 October 2012

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Balance of unallotted securities under scheme(s) from previous return:	1,040,000
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	1,040,000

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8 November 2012

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares		
Period of return:	From:	1 May 2012	To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:		163,606	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		163,606	

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date:8 November 2012

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS		
Period of return:	From:	1 May 2012	To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:		275,420	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		275,420	

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date:8 November 2012

Name of applicant:	GlaxoSmithKline plc
--------------------	---------------------

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Name of scheme:	SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary		
Period of return:	From:	1 May 2012	To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:		100,000	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		100,000	

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an Ris.

Date: 8 November 2012

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	GlaxoSmithKline Savings Related Share Option Scheme		
Period of return:	From:	1 May 2012	To: 31 October 2012
Balance of unallotted securities under scheme(s) from previous return:		4,005,708	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		115,727	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		3,889,981	

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 08, 2012

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc